Planview Reports Record Revenue Driven By Customer-Focused AI Innovation
Company Momentum and New Logo
Total 2025 expected revenue to approach $500 million.
Added more than 120 net new customers in the first half, including marquee names in healthcare, energy, and technology.
Acquired Sciforma, a prominent provider of Project Portfolio Management (PPM) and Product Development solutions, earlier this year.
Hosted in-person Planview Connect and Planview Day events, with more than 1,000 customers, prospects, and partners from all over the world participating to share best practices and experience new Planview innovations.
Key customer wins and expansions have driven Planview's continued profitable growth. In the first half of 2025, net new customers and notable customers who selected or expanded their footprint with Planview include: Currys Group, DHL, EDF Renewables, Farmacia Guadalajara, Fisher & Paykel Healthcare, FIS, General Mills, Getinge Sterilization, Harman Connected Services, HCSC, Infosys, John Lewis, KiwiBank, Lam Research, MDA Space, Novonesis, O'Reilly Automotive Stores, PPL Services Corporation, Progressive, QBE, RTX, Renesas, Royal Health, RS Group, Stryker, T. Rowe Price, UPS, and Vanderbilt University.
Planview Helps Leaders Harness AI-Driven Productivity
According to CIO's State of the CIO Survey 2025 1, 42% of CIOs say AI and machine learning (ML) are their top technology priorities for 2025. At the same time, more enterprises reported AI project failures this year compared to 2024, according to a survey conducted by S&P Global Market Intelligence 2. Planview closes out the first half of 2025 focused on addressing this gap – helping organizations cut through their own noise to deliver impact – with expanded AI capabilities throughout its solutions. Planview's AI-powered assistant for Connected Work, Planview® Copilot, allows teams to harness AI to deliver proactive insights and personalized recommendations to make informed decisions, optimize resources, and adapt to changes in real-time.
'We believe the future of connected work is delivered in an AI-first world—AI doesn't just enhance decision support; it accelerates the realization of our vision for seamless enterprise synchronization and orchestration. With AI woven into the fabric of our platform, we ensure connected work delivers tangible business outcomes,' said Razat Gaurav, Planview CEO. 'This is how we empower CIOs, CTOs, CFOs, and CEOs to harness AI‑driven productivity and stay competitive in today's fast‑moving market. What matters is outcome orientation and organizational alignment: connecting leadership strategy to frontline execution.'
'In the age of AI-driven change, this connected fabric ensures businesses can adapt rapidly, harness complex data landscapes, and seize emerging opportunities. And as AI continues democratizing intelligence, we're committed to guiding organizations through the opportunities and necessary guardrails to create sustained economic value.'
Maximizing Customer Value
Continuing its commitment to ensuring organizations can maximize the full potential of their investments in Planview to advance their most important company initiatives, Planview is partnering with Pendo, an industry-leading software experience management platform. First announced at Planview Connect 2025, Planview® Adopt helps organizations by simplifying the adoption of Planview solutions, while also creating higher user satisfaction, better end-user productivity, and improved operational efficiency.
Planview hosted its first in-person customer conference since 2019 in Miami, Fl.; followed by customer events in New Zealand, Germany, France, and the UK. Planview Connect and Planview Day events brought together over 1,000 global customers, prospects, and partners to share in best practices and explore Planview's newest innovations.
Industry and Leadership Recognition
Planview's commitment to excellence was recognized through multiple awards and analyst acknowledgments in the first half:
Planview Copilot, the AI-powered assistant for connected work, received two accolades:
DEVOPS Tech Ascension Award - Best AI/ML-Powered Solution award
2025 SaaS Awards – FINALIST for Best SaaS Product for Business Productivity
2025 Globee® Award for Technology - SILVER GLOBEE® for Strategic Portfolio Management and won best of category
2025 Top Rated Award from TrustRadius
Named a Leader in The Forrester Wave™: Value Stream Management (VSM) Solutions, Q2 2025
Planview Welcomes New Leaders
With a continued focus on delivering value and support to customers and scaling up global operations, the company has made strategic hires in key roles to provide exceptional value to our customers while driving sustainable growth for Planview. Sunny Saroya joins Planview as senior vice president of North America Sales, bringing world-class GTM and cross-functional collaboration experience, most recently at Anaplan, to Planview. Sunny will lead Planview Sales in North America. Sandrina Branton joins Planview as senior vice president of Professional Services, bringing extensive global leadership experience, most recently at ServiceNow, building and leading large Customer Success and Professional Services teams.
To learn more about Planview's vision for AI, visit: www.planview.com/ai.
About Planview
Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Yahoo
4 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Business Insider
17 hours ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
